Table 1 Demographic characteristics and induced sputum cell counts.
From: Sputum neutrophils as a biomarker in COPD: findings from the ECLIPSE study
Characteristic | Baseline (n = 359) | Year 1 (n = 297) |
|---|---|---|
Age (y) | 63.6 (6.86) | 63.4 (6.53) |
Gender, Male/Female | 225 (63%)/134 (37%) | 198 (67%)/99 (33%) |
Current/Former Smokers | 148 (41%)/211 (59%) | 120 (40%)/177 (60%) |
Number of pack years smoked | 49.2 (28.07) | 49.4 (27.97) |
Inhaled steroid users | 269 (75%) | 227 (76%) |
Long acting beta-agonist users | 279 (78%) | 244 (82%) |
Long acting anticholinergic users | 284 (79%) | 243 (82%) |
Post bronchodilator FEV1 % predicted | 50.2 (15.46) | 50.0 (15.94) |
Post bronchodilator FEV1 (L) | 1.368 (0.49) | 1.396 (0.52) |
Post bronchodilator FEV1/FVC ratio (%) | 44.5 (11.91) | 45.8 (11.94) |
GOLD Stage II | 180 (50%) | 154 (52%) |
GOLD Stage III | 141 (39%) | 110 (37%) |
GOLD Stage IV | 38 (11%) | 33 (11%) |
Sputum TCC (×10^6/ml) | 2.92 (4.92) | 3.32 (5.50) |
Sputum Neutrophil TCC (×10^6/ml) | 2.51 (4.59) | 2.89 (5.24) |
Sputum Macrophage TCC (×10^6/ml) | 0.33 (0.42) | 0.35 (0.53) |
Sputum Eosinophil TCC (×10^6/ml) | 0.028 (0.10) | 0.035 (0.13) |
Sputum Lymphocyte TCC (×10^6/ml) | 0.018 (0.04) | 0.015 (0.03) |
Sputum Neutrophil % | 78.9 (16.4) | 82.5 (15.0) |
Sputum Macrophage % | 16.9 (14.4) | 13.9 (13.1) |
Sputum Eosinophil % | 1.3 (2.6) | 1.3 (4.1) |
Sputum Lymphocyte % | 0.7 (0.8) | 0.5 (0.8) |
Sputum Epithelial % | 2.1 (4.51) | 1.7 (3.13) |